AstraZeneca reported a longer survival rate from its blockbuster cancer drug Tagrisso (osimertinib).
The LAURA2 Phase III trial showed Tagrisso with the addition of pemetrexed and platinum-based chemotherapy demonstrated an improvement in survival rates for patients with a form of advanced non-small cell lung cancer.
These results were presented at a world lung cancer conference.
Tagrisso plus chemotherapy demonstrated a median overall survival rate of nearly four years compared to about three years using Tagrisso alone..
Tagrisso plus chemotherapy reduced the risk of death by 23% compared to Tagrisso alone.
An estimated 63% of patients treated with the combination were alive at three years and 49% of patients were alive at four years compared to 51% and 41%, respectively, using Tagrisso alone.
David Planchard, MD, thoracic oncologist at Gustave Roussy Institute of Oncology, Villejuif, France, and principal investigator for the trial, said: “The fundamental goals of lung cancer treatment are to extend survival while preserving patients' quality of life. These compelling results, which demonstrated unprecedented median overall survival, show this combination can achieve both of these goals and support osimertinib, with or without the addition of chemotherapy, as the standard of care for patients with 1st-line advanced EGFR-mutated lung cancer. With two highly effective osimertinib-based options for these patients, physicians can better tailor treatment to individual needs and help ensure the best possible outcome for each patient.”
Susan Galbraith, executive vice president, Oncology Haematology R&D at AstraZeneca, said: “The latest FLAURA2 trial results set a new survival standard for patients, with Tagrisso plus chemotherapy demonstrating a median overall survival of nearly four years in firstt-line advanced EGFR-mutated lung cancer—surpassing the three-year benchmark established in the FLAURA trial. Over the past decade, Tagrisso has consistently delivered strong survival benefits and tolerable safety across all stages of non-small cell lung cancer, cementing its role as the backbone therapy in EGFR-mutated lung cancer.”
Tagrisso recorded estimated sales of $6.6 billion in 2024. Lung cancer remains the most widespread form of cancer. Pharma gaint Johnson & Johnson has a competing drug with comparable results, Fierce Pharma reported.
AstraZeneca employs about 1,600 in Delaware.
Sorry, an error occurred.
Already Subscribed!
Cancel anytime
Thank you .
Your account has been registered, and you are now logged in.
Check your email for details.
Submitting this form below will send a message to your email with a link to change your password.
An email message containing instructions on how to reset your password has been sent to the email address listed on your account.
No promotional rates found.
Secure & Encrypted
Thank you.
Your gift purchase was successful! Your purchase was successful, and you are now logged in.
| Rate: | |
| Begins: | |
| Transaction ID: |
A receipt was sent to your email.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.